Early Evaluation Of The Efficacy And Safety Of Abiraterone Acetate’s Treatment In Metastatic Castration Resistant Prostate Cancer

Objective: To evaluate the early efficacy and safety of abiraterone acetate’s treatment in metastatic castration resistant prostate cancerMethods: This study used a randomized, double-blind, placebo-controlled studies Subjects were m CRPC patients. The test group and the control group according to 2:1 distribution, the experimental group 12 cases, the control group of 6 cases, a total of 18 cases. Two groups of patients were orally once a day, 4 abiraterone acetate tablets(or placebo) each time(1000mg) with prednisone tablets 1(5 mg), twice a day. 28 days to 1 cycles were observed. When each period ends, PSA, ECG、blood routine, urine routine, liver function and blood electrolytes, renal function and blood biochemistry should be checked; and every 2 period ECT bone scan, whole-body CT were checked. The medical check up will be observed until the progress of the disease. Compared with the two groups of patients with PSA remission rate, PSA fall time, PSA progress time, focus on the reduction rate, pain relief time and adverse events.Results: strengthen the abiraterone with prednisone compared with placebo with prednisone PSA remission rate was 89% vs 0%; PSA decline time 116 months vs no decline; time to PSA progression 8.86 month vs2.8 month;lesions reduced ratio was 45.45% vs0%. 18 in 10 cases of adverse reactions, mainly for high blood pressure, bone pain aggravate, hypokalemia, elevated transaminases, no adverse reactions lead to stopping drugs occurred.Conclusion: The treatment of abiraterone acetate combined with prednisone for metastatic prostate cancer patients was well tolerated, It could prolong the patient’s time to PSA progression, improve the quality of life of patients, relieve bone pain level, and it’s expected to extend a patient’s life expectancy.